Ph-Negative Myeloproliferative Neoplasms: Diagnosis and Treatment Challenges in Russia (the Case of Saint Petersburg)

Mariya Olegovna Ivanova, E.V. Morozova, M.V. Barabanshchikova, B.V. Afanasyev,

DOI:

https://doi.org/10.21320/2500-2139-2021-14-1-45-52

Ph-negative myeloproliferative neoplasms (MPN) are rare oncohematological diseases characterized by long duration and indolence. World epidemiological data on these diseases considerably vary depending on geographical area and time frame of the study. The breakthrough in the understanding of MPN pathogenesis, observed in the early 2000s, enabled to elaborate approaches to differential diagnosis and treatment of Ph-negative MPNs as well as to improve their prognosis. Although these approaches are specified in the Russian clinical guidelines, physicians still face challenges in their implementation in practice. The present review provides a detailed description and analysis of literature data on epidemiology, pathogenesis, and principles of Ph-negative MPN diagnosis and treatment. It also describes the situation in Saint Petersburg as an example of existing challenges in management of patients with Ph-negative MPNs in Russia and offers potential solutions.

  • Mariya Olegovna Ivanova IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  • E.V. Morozova IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  • M.V. Barabanshchikova IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  • B.V. Afanasyev IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022 ; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022
  1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452–66. doi: 10.1056/NEJMra063728. DOI: https://doi.org/10.1056/NEJMra063728
  2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544. DOI: https://doi.org/10.1182/blood-2016-03-643544
  3. Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia Vera: Stem-Cell and Probable Clonal Origin of the Disease. N Engl J Med. 1976;295(17):913–6. doi: 10.1056/NEJM197610212951702. DOI: https://doi.org/10.1056/NEJM197610212951702
  4. Titmarsh GJ, Duncombe AS, Mcmullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581–7. doi: 10.1002/ajh.23690. DOI: https://doi.org/10.1002/ajh.23690
  5. Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011. J Cancer Res Clin Oncol. 2015;141(12):2131–8. doi: 10.1007/s00432-015-1983-5. DOI: https://doi.org/10.1007/s00432-015-1983-5
  6. Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–97. doi: 10.1111/ejh.12256. DOI: https://doi.org/10.1111/ejh.12256
  7. Byun JM, Kim YJ, Youk T, et al. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. Ann Hematol. 2017;96(3):373–81. doi: 10.1007/s00277-016-2902-9. DOI: https://doi.org/10.1007/s00277-016-2902-9
  8. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595–600. doi: 10.3109/10428194.2013.813500. DOI: https://doi.org/10.3109/10428194.2013.813500
  9. Shuvaev V, Martynkevich I, Abdulkadyrova A, et al. Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience. Blood. 2014;124(21):5556. doi: 10.1182/blood.v124.21.5556.5556. DOI: https://doi.org/10.1182/blood.V124.21.5556.5556
  10. Федеральный закон от 21 ноября 2011 г. № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации» [электронный документ]. Доступно по: https://minzdrav.gov.ru/documents/7025-federalnyy-zakon-323-fz-ot-21-noyabrya-2011-g. Ссылка активна на10.2020.
  11. [Federal Law of November 21, 2011 No. 323-FZ “On the fundamentals of public health protection in the Russian Federation”. [Internet] Available from: https://minzdrav.gov.ru/documents/7025-federalnyy-zakon-323-fz-ot-21-noyabrya-2011-g. (accessed 21.10.2020) (In Russ)]
  12. Schischlik F, Kralovics R. Mutations in myeloproliferative neoplasms–their significance and clinical use. Expert Rev Hematol. 2017;10(11):961–73. doi: 10.1080/17474086.2017.1380515. DOI: https://doi.org/10.1080/17474086.2017.1380515
  13. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90. doi: 10.1056/NEJMoa051113. DOI: https://doi.org/10.1056/NEJMoa051113
  14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. doi: 10.1016/j.ccr.2005.03.023. DOI: https://doi.org/10.1016/j.ccr.2005.03.023
  15. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054–61. doi: 10.1016/s0140-6736(05)71142-9. DOI: https://doi.org/10.1016/S0140-6736(05)71142-9
  16. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–8. doi: 10.1038/nature03546. DOI: https://doi.org/10.1038/nature03546
  17. Scott LM. The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol. 2011;86(8):668–76. doi: 10.1002/ajh.22063. DOI: https://doi.org/10.1002/ajh.22063
  18. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):1140–51. doi: 10.1371/journal.pmed.0030270. DOI: https://doi.org/10.1371/journal.pmed.0030270
  19. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood. 2006;108(10):3472–6. doi: 10.1182/blood-2006-04-018879. DOI: https://doi.org/10.1182/blood-2006-04-018879
  20. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. doi: 10.1056/NEJMoa1311347. DOI: https://doi.org/10.1056/NEJMoa1311347
  21. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. doi: 10.1056/NEJMoa1312542. DOI: https://doi.org/10.1056/NEJMoa1312542
  22. Harrison CN, Vannucchi AM. Closing the gap: Genetic landscape of MPN. Blood. 2016;127(3):276–8. doi: 10.1182/blood-2015-10-674101. DOI: https://doi.org/10.1182/blood-2015-10-674101
  23. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi: 10.1038/s41408-018-0054-y. DOI: https://doi.org/10.1038/s41408-018-0054-y
  24. Меликян А.Л., Ковригина А.М., Суборцева И.Н. и др. Ph-негативные миелопролиферативные заболевания. Клинические рекомендации. 2018 г. [электронный документ]. Доступно по: http://cr.rosminzdrav.ru/#!/recomend/96. Ссылка активна на 21.10.2020.
  25. [Melikyan AL, Kovrigina AM, Subortseva IN, et al. Ph-negative myeloproliferative neoplasms. Clinical guidelines. 2018. [Internet] Available from: http://cr.rosminzdrav.ru/#!/recomend/96. (accessed 21.10.2020) (In Russ)]
  26. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(12):1551–60. doi: 10.1002/ajh.25230. DOI: https://doi.org/10.1002/ajh.25230
  27. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–9. doi: 10.1038/leu.2013.119. DOI: https://doi.org/10.1038/leu.2013.119
  28. Vannucchi AM, Guglielmelli P, Rotunno G, et al. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood. 2014;124(21):405. doi: 10.1182/blood.v124.21.405.405. DOI: https://doi.org/10.1182/blood.V124.21.405.405
  29. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet HHS Public Access. Leukemia. 2018;32(5):1057–69. doi: 10.1038/s41375-018-0077-1. DOI: https://doi.org/10.1038/s41375-018-0077-1
  30. NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative Neoplasms. Version 2.2017. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf (accessed 11.2020).
  31. Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia Chromosome-Negative Chronic Myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v85–v99. doi: 10.1093/annonc/mdv203. DOI: https://doi.org/10.1093/annonc/mdv203
  32. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. N Engl J Med. 2015;372(5):426–35. doi: 10.1056/NEJMoa1409002. DOI: https://doi.org/10.1056/NEJMoa1409002
  33. Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97(9):1591–600. doi: 10.1007/s00277-018-3365-y. DOI: https://doi.org/10.1007/s00277-018-3365-y
  34. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 2014;120(4):513–20. doi: 10.1002/cncr.28441. DOI: https://doi.org/10.1002/cncr.28441
  35. Распоряжение Правительства Российской Федерации от 12 октября 2019 г. № 2406-р [электронный документ]. Доступно по: http://static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf. Ссылка активна на 21.10.2020.
  36. [Russian Federation government resolution of October 12, 2019 No. 2406-r. [Internet] Available from: http://static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf. (accessed 10.2020) (In Russ)]
  37. Постановление Правительства РФ от 26 апреля 2012 г. № 403 «О порядке ведения Федерального регистра лиц, страдающих жизнеугрожающими и хроническими прогрессирующими редкими (орфанными) заболеваниями, приводящими к сокращению продолжительности жизни граждан или их инвалидности, и его регионального сегмента» (с изменениями и дополнениями) [электронный документ]. Доступно по: http://base.garant.ru/70168888/. Ссылка активна на 21.10.2020.
  38. [Russian Federation government decree of April 26, 2012 No. 403 “On the rules for Federal Register of persons with life-threatening and chronic progressive rare (orphan) diseases leading to the reduction in life expectancy or disability, and its regional segment” (amended and revised.) [Internet] Available from: http://base.garant.ru/70168888/. (accessed 10.2020) (In Russ)]

Keywords:

myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, primary myelofibrosis

License

Copyright (c) 2021 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Mariya Olegovna Ivanova, MD, PhD, IP Pavlov First Saint Petersburg State Medical University, 6/8 L’va Tolstogo str., Saint Petersburg, Russian Federation, 197022, ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, ул. Льва Толстого, д. 6/8, Санкт-Петербург, Российская Федерация, 197022, e-mail: marilexo@yandex.ru

Downloads

Published

01.01.2021

Issue

Vol. 14 No. 1 (2021)
MYELOID TUMORS

How to Cite

Ivanova M.O., Morozova E.V., Barabanshchikova M.V., Afanasyev B.V. Ph-Negative Myeloproliferative Neoplasms: Diagnosis and Treatment Challenges in Russia (the Case of Saint Petersburg). Clinical Oncohematology. Basic Research and Clinical Practice. 2021;14(1):45–52. doi:10.21320/2500-2139-2021-14-1-45-52.

Most read articles by the same author(s)

1 2 3 4 > >>